Christine Foster

WEX Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceutical products for pain management. The pain management solutions are provided through its proprietary platform technology based on TTX (Tetrodotoxin). It owns and operates its research, development and manufacturing facilities in China through its subsidiaries. The company was founded on June 3, 1987 and is headquartered in Vancouver, Canada.

Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA.

Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ.

Archangel Investors Ltd. is a Private Equity firm, a subsidiary of Riverside Global Partners LLC founded in 1988 by Michael David Rutterford and Barry Edward Sealey. The firm is headquartered in Boston.

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from explicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bio products. Recombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge. CDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI's core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

Genetic Alliance, Inc. provides health care services through genetics. Its customers include parent and family groups, community organizations, professional societies, corporations, and government agencies. The company was founded by Joan O. Weiss in 1986 and is headquartered in Washington, DC.

Inomax LLC is an American venture capital company.

Part of General Electric Co., Datex-Ohmeda, Inc. develops and manufactures medical equipment. The company is based in Madison, WI.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA.

Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California.

Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA.

Blue Mesa Health, Inc. engages in the provision of digital therapeutics program to support the prevention diabetes and other chronic diseases. The company was founded by Misa Nuccio, Curtis Duggan, Evan Willms, Mike Benna, Jonathan Bixby, and Joshua Bixby in 2015 and is headquartered in New York, NY.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist.

Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton.

TFC Therapeutics, Inc. is a biotech company based in New York, NY. TFC Therapeutics is developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. The company is blending early-stage research with innovative platform design to develop next-generation treatments to eliminate the most resilient cancers and put an end to their recurrence before it begins. The company was founded in 2022 and Jennifer Power has been the CEO of the company since 2023.

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.